New data sharpen the apomorphine vs ropinirole debate

A new comparison is sharpening the conversation around emesis induction in dogs: recent research suggests ropinirole ophthalmic solution and apomorphine don’t perform quite the same way in practice. Ropinirole, marketed as Clevor, became the first FDA-approved drug to induce vomiting in dogs in June 2020, offering clinics an on-label, ophthalmic option instead of extra-label apomorphine. In early field and healthy-dog studies, ropinirole showed high overall efficacy, with vomiting typically occurring within about 10 to 12 minutes. But a 2025 comparative study in emergency patients found ropinirole had a lower first-dose success rate than apomorphine, took longer to trigger the first emetic event, and was more often associated with prolonged vomiting that required rescue antiemetic therapy. That trial, conducted at two specialty referral hospitals in 132 client-owned dogs with suspected toxin or foreign-body ingestion, also reflects the kinds of real ER cases clinicians actually see; dogs could be redosed at 20 minutes if they had not vomited, and outcomes included time to emesis, number of vomiting episodes, and need for reversal therapy. (fda.gov)

Why it matters: For veterinary professionals, the question is shifting from “does ropinirole work?” to “when is it the best choice?” Apomorphine remains familiar, fast, and highly effective, but it is used extra-label in the U.S. and carries handling and safety drawbacks, including hazardous-drug concerns and more serious CNS or respiratory adverse effects. Ropinirole offers the advantages of FDA approval, ready-to-use ophthalmic administration, and easier clinic workflow, but the newer comparative data suggest teams may need to plan for slower onset, possible redosing, and more frequent antiemetic reversal in some cases. And if prolonged vomiting does need to be stopped, clinics may soon have another practical tool on hand: Dechra says its newly approved maropitant injectable, Emeprev, is a bioequivalent antiemetic for dogs and cats that does not require refrigeration and is formulated with benzyl alcohol to reduce injection pain in dogs. (vetmed.illinois.edu)

What to watch: Expect more discussion in toxicology and emergency circles about case selection, redosing protocols, and whether newer head-to-head data change first-line emetic choices in canine practice. It will also be worth watching how clinics build rescue antiemetics into those protocols, especially as newer injectable maropitant options become available through distributors in early 2026. (pubmed.ncbi.nlm.nih.gov)